The prognostic role of systemic inflammatory markers on HIV-infected patients with non-Hodgkin lymphoma, a multicenter cohort study

Table 5 Cox regression analyses for mortality in the derivation sample

Variable	Category	Univariate analysis		Multivariate analysis ^π
		Univariate analysis		n subjects included = 93
		HR (95% CI)*	P value	HR (95% CI)*	P value
Gender	Male vs Female	1.03 (0.59-1.79)	NS
Age (years)		1.02 (1.0-1.05)	NS
IDU	Yes vs No	1.04 (0.66-1.66)	NS
AIDS defining event	Yes vs No	1.73 (1.09-2.73)	0.019	2.02 (1.01-4.02)	0.045
HBV or/and HCV co-infection	Yes vs No	0.94 (0.60-1.49)	NS
cART	Yes vs No	0.57 (0.35-0.95)	0.032
CD4 cell count, cell/mm3	<200 vs ≥200	1.79 (1.12-2.88)	0.015
HIV-RNA undetectable	Yes vs No	1.52 (0.84-2.73)	NS
PNI	<45 vs ≥45	2.42 (1.22-4.77)	0.011	2.21 (1.11-4.40)	0.023

Abbreviations: HR Hazard Ratio, 95% CI 95% Confidence Interval, IDU Intravenous Drug Use, HBV Hepatitis B Virus, HCV Hepatitis C Virus, cART combined Antiretroviral Therapy, PNI Prognostic Nutritional Index, NS Not Statistical Significant (p > 0.05).
*Adjusted for all the variables in the table. ^πThe mortality risk score based on the regression coefficients of the variables in final model was represented by 0.703*(AIDS defining event [yes =1/no = 0]) + 0.794 * (PNI) [AIDS defining event within six months from NHL diagnosis].

ISSN: 1479-5876